-+ 0.00%
-+ 0.00%
-+ 0.00%
Evogene Swings to Q3 Net Loss of $2.86 Million
Share
Listen to the news
Evogene Swings to Q3 Net Loss of $2.86 Million
  • Evogene swung to a third-quarter 2026 net loss of $2.86 million from net income of $5.2 million a year earlier.
  • Revenues fell 55% year-over-year to $141,000, mainly due to the Bayer license and collaboration agreement ending in May 2026.
  • Cash, cash equivalents and short-term bank deposits totaled approximately $9.2 million at September 30; third-quarter cash usage reached approximately $2.4 million.
  • The internal acute graft-versus-host disease drug discovery program advanced toward IND-enabling studies, with candidates showing nanomolar potency.
  • Subsidiary AgPlenus identified fungicide compounds that reduced Septoria disease severity by up to 75% versus untreated controls in plant tissue assays.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611190700PR_NEWS_USPR_____LN01514) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending